At meeting held on 27 June 2018
The Board of Jubilant Life Sciences has approved issuance of Redeemable Non-Convertible Debentures (NCDs) on private placement basis upto an amount of Rs. 350 crore. The proposed issue has been rated AA Stable by CRISIL as compared to AA- Stable for earlier NCD issue of Rs. 495 crore by India Ratings. The proceeds would be mainly utilised for repayment of the existing debt and to reduce the overall cost of borrowing.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
